The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
You would have to be stupid to buy in the open offer when you can get them cheaper on the open market. You might want to throw your money away on the open offer as a kind gesture to the Company who have continued to dilute your holding over the years.
I still think this will hit 5p IMHO
Looks like my prediction will be wrong. This could drop to 3p given the terrible news from Crumbs today. An RNS from Scancell is needed to clarify and if the Modi1 update is not great, the SP will be under huge pressure.
Not a time to buy IMHO. Wait on 3p
A biotech with a years funding is not enough for planning and future milestones. Scancell are no strangers to fund raising within a 1-2 year period.
My sophistication is shown in my correct assumptions on SP movement. Something that hurts the blinkered but they know they only have themselves to blame. Foul mouthing others gives them a sense of resilience but unfortunately they end up poorer.
You can follow GF123 and buy, buy, buy or you can take a more balanced view. With most Bio's, the II will dilute your holding of the SP will crash to zero.
Not much support from here to 5p apart from a brief upturn as the big sellers pause and PI's are duped before the selling re-starts. A 50% fall from here is not out of the question, it is probably more likely than a proportionate rise.
It's not looking good and the SP desperately needs good news to stem the fall.
Cash is running low, there will be more dilution soon.
More respect needed for balanced posts that argue against the mob.
No gloating, just a reality check for those who have spent years peddling the prospects for this company. The support has been broken today and it needs to recover this week above 11p or you are looking at a steep fall to my predicted 5p level.
Now back to 2020 levels, it's not a pretty picture or a promising one.